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To the Editor
Relapsed or refractory (R/R) chronic lymphocytic leukemia
(CLL) is frequently associated with the acquisition or
enrichment of chromosomal and molecular genetic features.
These include deletion of the short arm of chromosome 17
(del[17p]), mutations in the tumor-suppressor protein p53
gene (TP53), lack of somatic mutations in the variable
region of the immunoglobulin heavy chain, and others [1–
4]. Complex karyotype (CK) is deﬁned as at least three
distinct chromosomal abnormalities present in more than
one metaphase [5]. The presence of CK abnormalities is an
adverse prognostic factor and associated with inferior out-
comes in patients with CLL after treatment with che-
motherapies and targeted therapies [6–12].
Idelalisib—a selective inhibitor of phosphatidylinositol-
3-kinase delta—in combination with rituximab led to sig-
niﬁcant prolongation of progression-free survival (PFS) and
overall survival (OS) compared with that seen with ritux-
imab plus placebo in patients with relapsed CLL and sig-
niﬁcant comorbidities in a randomized, double-blind, phase
3 study (NCT01539512; the primary study) [13]. Patients
who progressed on the primary study could enroll in an
extension study (NCT01539291) to receive idelalisib
monotherapy [13]. The primary study was terminated pre-
maturely due to the superior efﬁcacy of idelalisib/rituximab
combination; patients still on treatment could also enroll in
the extension study. In this exploratory analysis, we
examined the clinical outcomes of idelalisib-treated patients
enrolled in the above-mentioned studies with or without
CK, as determined by peripheral blood lymphocyte
karyotyping.
From May 2012 to August 2013, 220 eligible patients
(Table S1) were randomly assigned to idelalisib/rituximab
(N= 110) or treatment with placebo/rituximab (N= 110) in
the primary study [13]. Overall, 161 patients enrolled in the
extension study initiated in October 2012. Samples for
metaphase spreads were obtained from all patients and were
processed (supplemental text) in two different laboratories
(NJ, USA; and Cologne, Germany). The samples processed
in the laboratory in Cologne had a karyotypic success rate
of 99%. The samples from the US sites were processed at
the US laboratory and were subsequently sent to Germany
for the karyotype analysis. Approximately half of the US
samples contained very few metaphases or metaphases with
poor quality; hence, karyotype analyses were performed
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successfully in only 51% of samples from the American
sites. Of the 220 patients randomized in the primary study,
successful stimulated karyotypes were obtained from 127
patients; 63/110 (57%) in the idelalisib arm and 57/110
(52%) in the placebo arm, with an overall karyotypic suc-
cess rate of 55% (Fig. S1). The proportion of CK-positive
and CK-negative patients was comparable between treat-
ment arms; 26/63 (41%) patients in the idelalisib arm and
24/57 (42%) patients in the placebo arm were CK-positive
(p= 1.000; Fig. S1). A listing of patients’ karyotypes is
provided in Table S2.
Demographic and baseline characteristics and prognostic
disease parameters for patients with successful karyotyping,
summarized in Table S3, were mostly balanced between the
CK and non-CK groups within each arm. Regardless of CK
status, most patients were male. Median age of patients with
and without CK was 69 and 73 years, respectively. All
patient subgroups were pretreated with a median of 3–3.5
prior therapies. More than 80% of the patients had anemia,
thrombocytopenia, or neutropenia of any grade at baseline.
A higher percentage of patients with CK (62%) also had del
[17p] and/or TP53 mutation compared with patients without
CK (43%; Table S3), although 38% of patients with CK did
not exhibit TP53 aberrations. Most patients had a high or
very high CLL-International Prognostic Index risk score
and a higher proportion of patients with CK were in the
“very high risk” group (Table S3). Demographic and
baseline characteristics were balanced between successfully
karyotyped patients and those who were not successfully
karyotyped (Table S4).
As of the August 16, 2018, ﬁnal cutoff, the median
(range) follow-up for the successfully karyotyped patients
in the idelalisib/rituximab arm was 29.2 (0.3, 67.6) months.
In patients treated with idelalisib/rituximab, the overall
response rates for CK-positive and -negative groups were
81% and 89%, respectively (odds ratio 0.5, p= 0.3509;
Table 1); all were partial responses.
PFS was comparable for patients treated with idelalisib/
rituximab, independent of the presence or absence of CK
(Fig. 1a). In the CK-positive and CK-negative groups,
median (Q1, Q3) PFS was 20.9 (8.5, not reached [NR])
months and 19.4 (16.4, 28.9) months, respectively. The
unadjusted hazard ratio (HR) (95% conﬁdence interval [CI])
for the difference between CK-positive vs CK-negative was
1.22 (0.60, 2.47; p= 0.5848).
Median (range) follow-up for CK-positive patients in the
idelalisib/rituximab arm was 16.8 (1.0, 64.4) months and
7.4 (0.2, 67.2) months for those in the placebo/rituximab
arm. With the two treatment groups combined, the median
(range) follow-up for CK-positive patients was 11.4 (0.2,
67.2) months. Among CK-positive patients, death occurred
in 13/26 (50%) patients treated with idelalisib/rituximab and
in 16/24 (66.7%) patients treated with placebo/rituximab.
Median (Q1, Q3) OS seemed longer in the CK-positive
group treated with idelalisib (28.3 [16.6, NR] months),
compared with 9.2 (2.0, 53.5) months in CK-positive
patients who received placebo/rituximab (Fig. 1b). The
unadjusted HR (95% CI) of 0.47 (0.23, 0.99; p= 0.0412)
showed favorable effect on OS with the idelalisib treatment.
No signiﬁcant difference in OS was noted between patients
with or without CK treated with idelalisib/rituximab.
Median (Q1, Q3) OS was 28.3 (16.6, NR) and 49.7 (25.5,
NR) months for the CK-positive and CK-negative group,
respectively, with unadjusted HR (95% CI) of 1.59 (0.77,
3.28) and p= 0.2099 (Fig. 1b). Co-presence of CK and del
[17p], TP53 mutation, or del[11q] did not signiﬁcantly
affect OS in patients treated with idelalisib/rituximab
(Fig. 1c). There were no differences in PFS and OS between
patients with vs without successful karyotyping (Table S5).
In this study, peripheral stimulated lymphocyte kar-
yotyping was performed in the context of a multicenter,
international, randomized trial. Our analysis suggests that
CK-positive patients treated with idelalisib/rituximab did
not exhibit a signiﬁcantly shortened survival compared with
those who were CK-negative. In addition, the primary
beneﬁcial effect of adding idelalisib to rituximab treatment
in R/R CLL patients with CK was reﬂected in OS pro-
longation compared to those who received only rituximab.
The deleterious impact of the presence of CK on clinical
outcomes in patients with R/R CLL after treatment with
various chemotherapeutic regimens or targeted therapies
has been well documented [6–12]. Interestingly, long-term
follow-up studies of patients receiving ibrutinib have shown
Table 1 Best overall response rate in the successfully karyotyped






ORR, n (%)a 21 (80.8) 33 (89.2)
95% CIb 60.6, 93.4 74.6, 97.0
Complete response 0 0
Partial response 21 (80.8) 33 (89.2)
Stable disease 3 (11.5) 2 (5.4)
Progressive disease 1 (3.8) 0
Not evaluable 1 (3.8) 2 (5.4)
Odds ratio for ORRc 0.5
95% CI for odds ratio 0.1, 2.1
p-value 0.3509
CI conﬁdence interval, CK complex karyotype, IRC Independent
Review Committee, ORR overall response rate
aORR is the percentage of patients who had best overall response of
complete response or partial response
b95% CI for ORR is based on the exact method
cOdds ratio and 95% CI are calculated without any adjustment
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varying results. Thompson et al. reported that in
88 R/R CLL patients treated with ibrutinib, after 3 years of
follow-up, CK was associated with shorter OS in both
univariate (25 months vs NR; p= 0.007) and multivariate
analyses (HR [95% CI], 5.9 [1.6–22.2], p= 0.008). In
addition, the survival of patients with CK was signiﬁcantly
inferior (p= 0.02) to the survival of patients without CK
[9]. In a 5-year follow-up of 132 patients treated with
ibrutinib in a phase 1b/2 study, median PFS and OS were
shorter for those with CK vs those without. Of interest,
when these results were further stratiﬁed by the presence or
absence of del[17p], the median PFS and OS of patients
with CK without del[17p] were considerably longer than of
those with del[17p]. Thus, after multivariate analyses, the
presence of CK was no longer signiﬁcantly associated with
PFS or OS, while the presence of del[17p] remained so [14].
In contrast, after a median follow-up of 19 months, no
signiﬁcant differences were observed in PFS or OS in
ibrutinib-treated patients with or without CK in a rando-
mized phase 3 study [15]. In this study, CK data were
missing from 22% of patients and the authors did recognize
that the relatively short follow-up time and incomplete data
limited the interpretability of their results.
Overall, the data presented here suggest a beneﬁcial
effect of idelalisib/rituximab vs rituximab alone on OS
regardless of CK status, even among patients who presented
with del[17p] or TP53 mutation. However, owing to the
small sample size employed for this post hoc analysis and
the possibility of competing causes of death from idelalisib-
related toxicities, these results should be re-evaluated in a
larger patient population. Another limitation of this study is
that the quality of the metaphase harvests was inconsistent,
since two different laboratories were used, and methodol-
ogies were not sufﬁciently harmonized as reﬂected by the
different success rates of the two laboratories. However, no
differences in PFS and OS were seen between patients with
vs without successful karyotyping when treated with ide-
lalisib/rituximab.
Our results, along with those presented for other targeted
therapies, indicate that further prospective, larger clinical
A B
C
Fig. 1 a Progression-free survival in patients with successful kar-
yotyping in the idelalisib arm. b Overall survival in patients with
successful karyotyping. c Forest plot of hazard ratios for OS by pre-
speciﬁed subgroups and the presence or absence of complex karyotype
in the idelalisib arm. CI conﬁdence interval, CK complex karyotype,
HR hazard ratio, IDELA idelalisib, IGHV immunoglobulin heavy-
chain variable region gene, LCL lower conﬁdence limit, no CK no
complex karyotype, NR not reached, OS overall survival, PBO pla-
cebo, PFS progression-free survival, R rituximab, UCL upper
conﬁdence limit
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studies are needed to guide individualized treatment deci-
sions in patients with R/R CLL and CK and provide gui-
dance on treatment sequencing. In addition, it may be
worthwhile to consider chromosome banding as an addi-
tional prognostic risk factor.
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